Artificial Intelligence in Public Health: Current Trends and Future Possibilities, 3rd Edition

Topic Information

Dear Colleagues,

Since the COVID-19 pandemic, we have witnessed a profound and lasting increase in scientific and societal interest in the development and application of Artificial Intelligence (AI) in the health domain. The pandemic served as a pivotal a turning point, exposing the fragility of health systems while underscoring the critical importance of data-driven, scalable, and adaptive solutions for managing complex public health challenges.

In this context, AI research has become strategically vital in the evolution of health systems and is inextricably linked to the broader development of digital health. This includes the collection, monitoring, integration, and management of health-related data, as well as the optimization of hospital infrastructures and interconnected governmental information systems. Technologies such as wearable monitoring devices, big data analytics, and robotics have already demonstrated their value in supporting diagnosis, treatment, and care pathways.

At the same time, the scope and capabilities of AI have expanded significantly beyond traditional machine learning and pattern recognition. Recent advances—particularly in generative AI and large language models (LLMs)—are transforming how knowledge is produced, accessed, and applied. These technologies are reshaping scientific communication, clinical documentation, citizen engagement, and decision-making processes, enabling new forms of interaction between individuals, professionals, and health systems.

Simultaneously, the emergence of computational modeling and digital twins offers innovative perspectives for simulating biological processes, patient-specific conditions, and even population-level dynamics. These tools enable the exploration of “what-if” scenarios, supporting prevention strategies, policy design, and system-level resilience.

Artificial intelligence applications continue to permeate a wide range of domains, including: organ, functional tissue, and cellular diagnostics; care robotics assisting in interventions, rehabilitation, and communication; biomedicine, from genetics to advanced modeling; and precision and personalized medicine. These established areas remain fundamental, especially when integrated with new AI paradigms and translated into scalable solutions.

A statement attributed to Henry Ford reminds us that “real progress happens only when the advantages of a new technology become available to everybody”. In this sense, the consolidation of AI technologies in health should aim to generate benefits for all stakeholders—from institutions to professionals, and ultimately to citizens and patients—promoting accessibility, inclusiveness, and equity of care.

Within this evolving landscape, public health plays a central and unifying role. AI has the potential to profoundly impact the following:

• The prevention of disease onset at both individual and population levels;
• The provision of personalized care and assistance within community and system contexts;
• The understanding of disease trends and the influence of biological, environmental, and behavioral determinants;
• The organization and optimization of healthcare services, including diagnostic and decision-making processes;
• The design, implementation, and evaluation of public health policies.

Through AI, big data can be leveraged to predict diseases and identify risk patterns across populations, enabling early interventions and targeted prevention strategies. At the same time, wearable and connected technologies allow continuous monitoring of individuals, supporting adaptive and personalized care pathways that can be scaled to population-level insights.

Furthermore, the synergy between AI immersive technologies—such as virtual reality and augmented reality—is pioneering new forms of digital health services, including remote care, training, rehabilitation, and simulation environments. These innovations contribute not only to clinical practice but also to public health preparedness and education.

However, the rapid expansion of AI also raises critical ethical, legal, and societal challenges, including issues related to transparency, accountability, bias, data protection, and governance. In addition, there is an increasing need for interdisciplinary education and training to equip professionals with the skills required to apply these technologies effectively and responsibly.

This Topic provides a comprehensive platform to explore both consolidated applications and emerging frontiers of AI in health, with a particular emphasis on public health perspectives, while remaining open to interdisciplinary and clinical contributions that demonstrate clear implications for population health, health systems, and societal impact.

We invite contributions that address the research, development, validation, and application of AI in current and future scenarios, fostering dialogue between technological innovation and public health needs.

In this Topic, original research articles, reviews, commentaries, opinions, viewpoints, communications, and brief reports are welcome. Research areas may include (but are not limited to) the following:

• Artificial neural networks
• Deep learning
• Generative AI and large language models (LLMs)
• Natural language processing
• Social intelligence
• Digital twins and computational modeling
• Big data and real-world data analytics
• Care robotics
• Virtual reality and augmented reality
• Medical decision making
• Disease monitoring, prediction, diagnosis, and classification
• Patient monitoring and wearable technologies
• Public health surveillance and epidemiology
• Health system organization and management
• Diagnostic imaging
• Digital pathology
• Digital radiology
• Ethical, legal, and social implications of AI
• Education and training in AI for health and public health

We look forward to receiving your contributions.

Prof. Dr. Daniele Giansanti
Dr. Giovanni Costantini
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
AI ai	5.0	6.9	2020	19.2 Days	CHF 1800	Submit
Bioengineering bioengineering	3.7	5.3	2014	17 Days	CHF 2700	Submit
Clinics and Practice clinpract	2.2	2.8	2011	25.7 Days	CHF 1800	Submit
Healthcare healthcare	2.7	4.7	2013	22.4 Days	CHF 2700	Submit
International Journal of Environmental Research and Public Health ijerph	-	8.5	2004	29.5 Days	CHF 2500	Submit
Journal of Clinical Medicine jcm	2.9	5.2	2012	18.5 Days	CHF 2600	Submit
Journal of Imaging jimaging	3.3	6.7	2015	18 Days	CHF 1800	Submit
Medical Sciences medsci	4.4	8.7	2013	18.7 Days	CHF 1600	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Bioengineering Clinics and Practice Healthcare J. Imaging JCM AI Medical Sciences IJERPH

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

21 pages, 2117 KB  

Open AccessArticle

Machine Learning-Based Survival Prediction in Early-Stage Non-Small Cell Lung Cancer: Development and Cross-National External Validation

by Nikhil Joshi, Hari Ponnamma Rani, Maxim Shevtsov and Thyageshwar Chandran

J. Clin. Med. 2026, 15(10), 3701; https://doi.org/10.3390/jcm15103701 - 11 May 2026

Viewed by 289

Abstract

Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide. However, prognostic models developed within a specific population may not be accurate when applied to another population due to differences in demographics and clinical practices. In the present study, we [...] Read more.

Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide. However, prognostic models developed within a specific population may not be accurate when applied to another population due to differences in demographics and clinical practices. In the present study, we investigated the cross-national applicability of machine learning (ML)-based survival prediction models trained on population data from the United States and validated on an independent Chinese clinical cohort. Methods: Cox proportional hazards, Random Survival Forest (RSF), and XGBoost-Cox models were developed and externally validated. Model discrimination was evaluated using the concordance index (C-index) and time-dependent AUC at 1, 3, and 5 years, along with calibration and decision curve analysis. Hyperparameter tuning was performed using cross-validation to reduce overfitting and improve model generalizability. Results: Three survival prediction models were developed using the U.S. SEER database (n = 13,260) and externally validated in an independent Chinese cohort (n = 505). Baseline characteristics differed between the cohorts, with the Chinese cohort being younger and having a higher proportion of stage IA disease. Despite these differences, all models demonstrated acceptable discrimination. The RSF model was the most stable across cohorts and time horizons, with a C-index of 0.740 (95% CI: 0.735–0.746) in SEER and 0.782 (95% CI: 0.720–0.844) in the Chinese cohort. RSF showed good calibration at 1 and 3 years but slightly overestimated 5-year mortality risk in the Chinese cohort. Conclusions: Machine learning-based survival prediction models, such as the Random Survival Forest model, are promising and robust tools for predicting cross-population survival in early-stage non-small cell lung cancer (NSCLC). However, differences in patient characteristics and treatment patterns may influence long-term model performance. These findings highlight the potential of flexible machine learning models in oncology and the essential role of rigorous external validation. Full article

(This article belongs to the Topic Artificial Intelligence in Public Health: Current Trends and Future Possibilities, 3rd Edition)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1